- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02899286
Efficacy and Safety Study of Recombinant Human Arginase 1 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase II Open-label Study of the Efficacy and Safety of Recombinant Human Arginase 1 (PEG-BCT-100) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Study Overview
Detailed Description
This is a phase 2, non-randomised, open-label study that aims at evaluating the efficacy of single agent PEG-BCT-100 in adult patients with relapsed/refractory AML. Eligible patients will receive intravenous (IV) infusion of PEG-BCT-100 weekly until disease progression, unacceptable drug-related toxicity(ies), allogeneic haematopoietic stem cell transplantation or withdrawal of subject consent.
Pharmacokinetic (PK) of PEG-BCT-100 and pharmacodynamics (PD) activity of PEG-BCT-100 on arginine depletion will be evaluated throughout the study. Plasma arginine level, intracellular blast arginine level (IBAL) in peripheral blood (PB) and bone marrow (BM) will be measured at specific time points. PEG-BCT-100 will be given once weekly at 1600 Units/kg (2.7mg/kg) per dose for three weeks (Cycle 1). If the post-treatment IBAL-BM examined within 5 days prior to each cycle fails to drop at least 70% from baseline value and disease response fails to achieve complete remission (CR) or complete remission with incomplete blood count recovery (CRi), PEG-BCT-100 may be increased to 2500 U/kg (the maximum tolerated dose as reported previously) at investigator's discretion. Disease response will be assessed within 5 days prior to each cycle according to the International Working Group (IWG) AML Response Criteria.
Safety and toxicity will be assessed through physical examinations, vital signs, blood tests and urinalysis throughout the study. Adverse event (AE) and serious adverse events (SAE) will be reported according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 4.03 (CTCAE v4.03) until 28 days after the last dose of PEG-BCT-100.
Immunogenicity response including anti-drug antibody (ADA) level and neutralizing antibody level will be assessed weekly for the first 2 cycles of PEG-BCT-100, pre-dose of each cycle thereafter and End of Study (EoS). Specific response predictive biomarkers in circulating and BM blasts, and emerging genetic markers will also be explored in the study.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Hong Kong, Hong Kong
- The University of Hong Kong, Queen Mary Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients ≥18 year-old at the time of informed consent
- Documented relapsed or refractory AML after at least two standard chemotherapy regimen or in whom the treating physicians considered unfit for further chemotherapy treatment
- The Eastern Cooperative Oncology Group (ECOG) performance status equal or less than 2
- Patients from whom valid consent is obtained
Exclusion Criteria:
- Patients who have received any induction chemotherapy, investigational treatment and arginine depleting agent within 2 weeks prior to the start of the PEG-BCT-100 (not including hydroxyurea or thioguanine)
- Any toxic effects (except hair loss) of the prior therapy have not been resolved to Grade 1 or less according to National Cancer Institute Common Terminology Criteria for Adverse Events
- Total bilirubin > 1.5 x Upper Limit of Normal (ULN) not related to haemolysis or Gilbert's disease, and ratio of concentrations of aspartate transaminase and alanine transaminase (AST/ALT) > 5 x ULN
- Creatinine > 2 x ULN or estimated glomerular filtration rate using Modification of Diet in Renal Disease formula < 60 ml/min/1.73 m2
- Second active malignancy within the past year except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast
- Uncontrolled concomitant illness including, but not limited to symptomatic congestive heart failure, unstable angina pectoris or cardiac arrhythmia
- History of HIV-1 seropositivity
- Active infection not adequately responding to appropriate therapy
- Patient is pregnant or lactating
- Female with childbearing potential who is not willing to use contraceptive methods which, in the opinion of the investigator, are effective and adequate while on study treatment and for 6 months after the last dose of study treatment
- Male with a female partner with childbearing potential who is not willing to use contraceptive methods which, in the opinion of the investigator, are effective and adequate while on study treatment and for 6 months after the last dose of study treatment
- Any condition that is unstable or can jeopardize the safety of the patients and their compliance to the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PEG-BCT-100
PEG-BCT-100 (PEGylated recombinant human arginase)
|
PEGylated recombinant human arginase
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Complete remission (CR) rate
Time Frame: 3 years
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: 3 years
|
3 years
|
|
Overall survival (OS)
Time Frame: 3 years
|
3 years
|
|
Overall response rate (ORR)
Time Frame: 3 years
|
proportion of patients achieving CR or CRi or partial remission (PR)
|
3 years
|
Duration of remission
Time Frame: 3 years
|
3 years
|
|
Time to progression (TTP)
Time Frame: 3 years
|
3 years
|
|
AE and SAE
Time Frame: 3 years
|
Incidence of AE and SAE by severity grading as assessed according to CTCAE v4.03
|
3 years
|
PK - Area under the plasma concentration versus time curve (AUC)
Time Frame: 2 years
|
2 years
|
|
PK - Peak plasma concentration of PEG-BCT-100 after administration (Cmax)
Time Frame: 2 years
|
2 years
|
|
PK - Lowest concentration that PEG-BCT-100 reaches before the next dose is administered (Cmin)
Time Frame: 2 years
|
2 years
|
|
PK - clearance
Time Frame: 2 years
|
2 years
|
|
PK - volume of distribution
Time Frame: 2 years
|
2 years
|
|
PK - elimination half-life
Time Frame: 2 years
|
2 years
|
|
PD
Time Frame: 2 years
|
arginine depletion
|
2 years
|
PK/PD relationship
Time Frame: 2 years
|
dose response
|
2 years
|
Anti-drug antibody (ADA)
Time Frame: 2 years
|
amount of ADA in patient sample (ng/mL)
|
2 years
|
neutralizing anti-drug antibody (nADA)
Time Frame: 2 years
|
amount of nADA in patient sample (ng/mL)
|
2 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Anskar Leung, The University of Hong Kong
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BCT-100-007
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
Clinical Trials on PEG-BCT-100
-
Bio-Cancer Treatment International LimitedThe University of Hong KongCompletedHepatocellular CarcinomaHong Kong
-
University of BirminghamCompletedCancer | Pediatric ALL | Pediatric Solid Tumor | Pediatric AMLUnited Kingdom, Australia, Netherlands
-
Bio-Cancer Treatment International LimitedOncotherapeuticsCompletedMelanoma | Prostate AdenocarcinomaUnited States
-
Bio-Cancer Treatment International LimitedThe University of Hong KongTerminated
-
Bio-Cancer Treatment International LimitedThe University of Hong Kong; Chinese University of Hong KongCompletedHepatocellular Carcinoma | NeoplasmHong Kong
-
Bio-Cancer Treatment International LimitedThe University of Hong Kong; Chinese University of Hong KongCompletedHepatocellular CarcinomaHong Kong
-
Bio-Cancer Treatment International LimitedThe University of Hong Kong; Chinese University of Hong KongCompletedHepatocellular Carcinoma | NeoplasmHong Kong
-
University of ArizonaNational Cancer Institute (NCI); National Institutes of Health (NIH)Not yet recruitingBreast CancerUnited States
-
Regen Lab SACompleted
-
Sichuan UniversityAffiliated Hospital of North Sichuan Medical College; Affiliated Hospital of...Completed